Table 1.
Nanomedicines in clinical development
| Targeting ligand |
Therapeutic encapsulated |
Indication | Clinical status |
|
|---|---|---|---|---|
| Liposomes | ||||
| ALN-TTR02 (NCT01559077) | Passive | siRNA | Transthyretin amyloidosis | Phase II |
| CALAA-01 (NCT00689065) | Transferrin | siRNA | Solid tumors | Phase I |
| CPX-351 (NCT00822094) | Passive | Cytarabine and daunorubicin | Acute myeloid leukemia | Phase III |
| MBP-426 (NCT00964080) | Transferrin | Oxaliplatin | Gastroesophageal adenocarcinoma | Phase II |
| SGT53-01 (NCT00470613) | Antibody fragment | p53 gene | Solid tumors | Phase I |
| TKM-PLK1 (NCT01262235) | Passive | siRNA | Solid tumors | Phase II |
| Polymeric NPs | ||||
| BIND-014 (NCT01300533) | Small molecule | Docetaxel | Solid tumors | Phase II |
| Atu027 (NCT01808638) | Protein kinase N3 | siRNA | Solid tumors | Phase II |
| CRLX-101 (NCT01380769)/(NCT00333502)/(NCT02010567) | Passive | Camptothecin | Non-small cell lung cancer/rectal cancer/renal cell carcinoma | Phase II |